-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

758 Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation

Program: Oral and Poster Abstracts
Type: Oral
Session: 641. Chronic Lymphocytic Leukemia: Basic and Translational: CLL and Richter Transformation: Functional Genomics and Molecular Mechanisms
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Lymphoid Leukemias, Translational Research, CLL, Genomics, Diseases, Lymphoid Malignancies, Biological Processes, Pathogenesis
Monday, December 9, 2024: 10:45 AM

Marwan Kwok, MD, PhD, FRCPath, MRCP1,2,3,4,5, Catherine Gutierrez, MD, PhD1,2,3, Neil Ruthen1*, Peyton Waddicor1,2*, Tamara Ouspenskaia3*, Christina Curran1,6*, Doris Fu3,7*, Binyamin Knisbacher, PhD3,8, Anat Biran, PhD1*, Adi Nagler, PhD1,2,3*, Aviv Liani1,6*, Sarah Chen3*, Gregory Lazarian, PharmD1,9,10*, Elizabeth Witten11*, Gabriela Brunsting Hoffmann1*, Emma Lin1*, Lucas Pomerance1,2*, Shuqiang Li, PhD1,3,12*, Lili Wang, MD, PhD13,14, Kenneth J. Livak, PhD1,12*, Donna S. Neuberg, ScD15, Gad Getz, PhD3,16,17*, Elisa Ten Hacken, PhD1,18 and Catherine J. Wu, MD1,2,3*

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Harvard Medical School, Boston, MA
3Broad Institute of MIT and Harvard, Cambridge, MA
4Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
5Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, Birmingham
6Northeastern University, Boston, MA
7Massachusetts Institute of Technology, Cambridge, MA
8Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel
9INSERM U978, Université Sorbonne Paris Nord, Bobigny, France
10Hematology Laboratory, Avicenne University Hospital, Assistance Publique – Hôpitaux de Paris, Bobigny, France
11Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
12Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA
13Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA
14Department of Systems Biology, City of Hope, Duarte, CA
15Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
16Department of Pathology, Massachusetts General Hospital, Boston, MA
17Krantz Family Center for Cancer Research and Dept. of Pathology, Massachusetts General Hospital, Boston, MA
18Division of Hematology and Medical Oncology, Weill Cornell Medical College, Weill Cornell Medicine, New York City, NY

The ribosomal protein RPS15 is recurrently mutated in chronic lymphocytic leukemia (CLL) and confers adverse prognosis. While translational rewiring is a recognized consequence of RPS15 mutation (RPS15-mut), its impact on genome stability and the precise mechanisms governing RPS15-mut driven B-cell leukemogenesis remain unclear. To delineate the sequence of cellular events that underlie malignant transformation and progression in the context of RPS15 mutation, we functionally interrogated a conditional knock-in mouse model of the RPS15-S138F mutation established using the Cd19-Cre/loxP system (Gutierrez et al, ASH 2020). Despite enrichment for Myc target genes in pre-leukemic Rps15-mut B splenocytes, these cells displayed a hypoproliferative phenotype characterized by increased G1 cell cycle checkpoint activation and reduced ex vivo proliferative capacity accompanied by increased apoptosis, compared to Rps15-WT splenocytes.

We hypothesized that decreased proliferation and increased apoptosis could result from a p53-mediated response to cellular stress arising from Rps15 mutation. Informed by the genomic landscape of CLL developing in older Rps15-mut mice that displayed an enrichment of A•T>C•G and C•G>T•A transversions indicative of peroxide-induced DNA damage, we interrogated the transcriptomes of Rps15-mut pre-leukemic B splenocytes, which showed upregulation of reactive oxygen species (ROS) genes (NES 1.5, p<0.05). We experimentally quantified mitochondrial ROS which confirmed increased oxidative stress in Rps15-mut compared to Rps15-WT splenocytes (p<0.001). We reasoned that unresolved oxidative stress could lead to DNA damage accumulation. Accordingly, we demonstrated increased γH2AX accumulation, a marker of DNA damage, in Rps15-mut B splenocytes compared to their Rps15-WT counterparts (p=0.01), as well as hypersensitivity of Rps15-mut splenocytes to oxidative stress overload with parthenolide (p=0.0009). RPS15 is known to stabilize p53 via MDM2 inhibition, hence Rps15-mut cells exhibited reduced p53 expression. Nevertheless, in response to DNA damage, p53 and p21 were significantly induced, the latter a p53-dependent mediator of G1 checkpoint activation, highlighting the functional importance of residual p53 activity in Rps15-mut B cells.

Given their heightened level of DNA damage, we further hypothesized that Rps15-mut pre-leukemic B splenocytes are hyper-dependent on DNA damage response (DDR). Conversely, defective DDR could precipitate genomic instability and facilitate acquisition of additional genomic alterations, such as TP53 deletion or loss-of-function mutation, that might promote transition toward a hyperproliferative or malignant state. To determine whether Rps15-mut B splenocytes could effectively respond to further genomic insults, we assessed cellular response to hydroxyurea (HU) and ionizing radiation (IR) that induce replication stress and DNA double-strand breaks (DSBs) respectively. While the ATR-Chk1 response to HU was preserved, the ATM-Chk2 response to IR was defective with diminished phosphorylation of downstream ATM targets and impaired induction of G2/M arrest. Indeed, Rps15-mut B cells subsequently acquired a spectrum of additional mutations and chromosomal alterations (e.g. Myc/Mapk amplification, Trp53 loss) that reflect genomic instability secondary to defective DDR.

Finally, we postulated that translational defects directly contribute to oxidative DNA damage accumulation and genomic instability in Rps15-mut B cells. We therefore performed ribosome profiling that showed differential translation efficiency (TE) in 342 genes between Rps15-mut and Rps15-WT B splenocytes, with significant enrichment of DNA replication, DDR and cell cycle genes by GSEA that was recapitulated in RPS15-mut vs WT isogenic HG3 CLL cell lines. In particular, Gpx1, a glutathione peroxidase that functions as a key cellular antioxidant, was confirmed by western blot to be downregulated in Rps15-mut B cells secondary to reduced TE (0.6-fold change vs WT, p=0.018), alongside other proteins important for the amelioration of oxidative DNA damage and DSBs (e.g. Cyb5r4, Otud4, Fance, Tlk1). Our analyses thus link RPS15-induced translational alterations with a cascade of cellular defects that compromise genome stability and highlight the critical nature of these defects in B-cell transformation and CLL progression.

Disclosures: Waddicor: Novartis: Current Employment, Current equity holder in private company. Lazarian: AsrtraZeneca: Honoraria; JANSSEN: Honoraria. Livak: MBQ Pharma Inc.: Membership on an entity's Board of Directors or advisory committees. Neuberg: Madrigal Pharmaceutical: Current equity holder in publicly-traded company. Getz: IBM, Pharmacyclics/Abbvie, Bayer, Genentech, Calico, and Ultima Genomics: Research Funding; Scorpion Therapeutics: Consultancy, Current equity holder in private company, Other: Founder; Broad Institute: Patents & Royalties: MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSEye, and MinimuMM-seq; PreDICTA Biosciences: Consultancy, Current equity holder in private company, Other: Founder. Wu: Repertoire: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Research Funding; BioNtech, Inc: Current equity holder in publicly-traded company; Aethon Therapeutics: Membership on an entity's Board of Directors or advisory committees; Adventris: Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH